Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves Pfizer’s HYMPAVZI to treat haemophilia
Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A and B.
FDA Approves Hympavzi for Hemophilia Treatment, Offering Novel Approach to Bleeding Disorder Management
The U.S. Food and Drug Administration (FDA) has approved Hympavzi (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing bleeding episodes in patients aged 12 and older
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi,
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency), or hemophilia B (congenital factor IX deficiency).
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
FDA Approves Hympavzi for Hemophilia A and B
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age 12 or older with hemophilia A or B without inhibitors (neutralizing antibodies), according to a news release published today.
FDA Approves New treatment option for cutting bleeding in Hemophilia A or B
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII (FVIII) or IX (FIX), respectively. Patients with these hemophilias
Hympavzi Approved for Treatment of Hemophilia A or B
Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.
USFDA gives nod to Pfizer’s drug therapy for patients with Hemophilia
Today’s approval of Hympavzi provides patients with hemophilia a new treatment option that is the first of its kind to work by targeting a protein in the blood clotting process,” said Ann Farrell, M.D.
The American Journal of Managed Care
5h
Navigating the “Really Exciting” Specialty Pharmaceutical Pipeline
Experts explored the latest trends, approvals, and pipeline developments in cell and gene therapies, rare disease, immunology ...
Medpage Today on MSN
6d
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
2d
FDA approves Hympavzi for hemophilia
The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Hamas leader Sinwar killed
Preliminary cause of death
Panel calls for 'reform'
Charged with theft
Fox News interview
100-yr-old capsule unveiled
Disney to debut new pass
NH justice indicted
Italy expands surrogacy ban
Gets minimum 28 years
US jobless claims fall
Antisemitic billboard hack
Synthetic nicotine pouches
FDA halts Novavax trial
Microscopic world photos
AL voter roll purge blocked
Sentenced for cartel bribery
Constitution copy auction
Abortion group sues Florida
Allows EPA emissions rule
$425M military aid for UKR
US strikes Houthi targets
More loan forgiveness
Meta confirms layoffs
To cut up to 2,500 jobs
GA election rules blocked
To settle US bribery probe
Feedback